Edwards Lifesciences has acquired Innovalve Bio Medical Ltd. to enhance its transcatheter mitral valve replacement technologies, addressing unmet patient needs and supporting long-term growth.

Target Information

Edwards Lifesciences (NYSE: EW) has successfully exercised its option to acquire Innovalve Bio Medical Ltd., a pioneering early-stage company specializing in transcatheter mitral valve replacement (TMVR) technologies. This acquisition follows Edwards' initial investment in Innovalve in 2017, which has since yielded promising early clinical results in their TMVR program. The integration of Innovalve's advancements into Edwards' existing portfolio is expected to significantly enhance the company’s capabilities in addressing substantial unmet needs in the structural heart patient population.

With Innovalve joining Edwards' transcatheter mitral and tricuspid therapies (TMTT) product group, led by corporate vice president Daveen Chopra, the acquisition marks a strategic expansion for the company. The synergy between Innovalve’s innovations and Edwards’ established expertise positions Edwards to offer a broader range of differentiated therapies for patients with mitral valve diseases.

Industry Overview

The transcatheter heart valve devices market is experiencing considerable growth globally, driven by an increasing aging population and a rising prevalence of heart valve diseases. In particular, Europe has emerged as a significant market for transcatheter technologies, with regula